Fennec Pharmaceuticals (FENC) Gains from Sales and Divestitures (2021 - 2022)
Fennec Pharmaceuticals posted quarterly Gains from Sales and Divestitures of $26000.0 for Q4 2022, down 23.53% year-on-year from $34000.0 in Q4 2021, and down 23.53% on a QoQ basis from $34000.0 in Q4 2021.
Fennec Pharmaceuticals (FENC) has 2 years of Gains from Sales and Divestitures data on file, last reported at $26000.0 in Q4 2022.
- For the quarter ending Q4 2022, Gains from Sales and Divestitures fell 23.53% year-over-year to $26000.0; the trailing twelve-month figure through Dec 2022 stood at $26000.0 (down 23.53% YoY), and the FY2022 full-year result was $26000.0, down 23.53% from the prior year.
- Gains from Sales and Divestitures for Q4 2022 stood at $26000.0, down from $34000.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $34000.0 in Q4 2021 and bottomed at $26000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 26,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Dec 31, 2021 | 34,000.00 |